GSK’s Shingrix Gains EC Approval for Ready-to-Use Prefilled Syringe

GSK’s Shingrix Gains EC Approval for Ready-to-Use Prefilled Syringe

GSK announced that the European Commission (EC) has approved a new prefilled syringe presentation for Shingrix (Recombinant Zoster Vaccine, Adjuvanted; RZV), a key advancement designed to streamline vaccine administration. Previously, Shingrix required reconstitution by mixing a lyophilised powder antigen vial with a liquid adjuvant suspension. The new ready-to-use prefilled syringe eliminates this step, offering healthcare professionals a more convenient option without altering the vaccine’s composition, efficacy, safety profile, indication, or two-dose regimen.

Next-Generation Skin Drug Delivery: Artificial Intelligence Solutions for Enhanced Therapeutic Precision and Barrier Navigation

Next-Generation Skin Drug Delivery: Artificial Intelligence Solutions for Enhanced Therapeutic Precision and Barrier Navigation

The article explores how artificial intelligence (AI) is transforming transdermal drug delivery systems (TDDS), offering innovative solutions to traditional challenges in drug administration. TDDS provides advantages over conventional oral and injectable methods by bypassing liver metabolism and enabling controlled drug release, but faces limitations due to the skin’s natural barrier properties.